Eosinophilic Asthma Treatment Market: Overview
Asthma associated with high level of eosinophils (white blood cells) is known as eosinophilic asthma. Patients with this form of asthma suffer from inflamed airways, which are blocked by fluid and mucus. They also experience spasms that cause difficulty in breathing. Eosinophilic asthma is characterized by abnormally high levels of eosinophils in the blood, affecting sinuses, nasal passage, and the lower airways. The condition is found to be common among people aged between 25 and 35.
Eosinophilic Asthma Treatment Market: Key Trends
The global eosinophilic asthma treatment market is projected to witness strong growth during the forecast period. This is attributed to increase in the number of regulatory approvals in developed countries, rise in prevalence of asthma, surge in demand for biologic therapies such as monoclonal antibodies & small molecule inhibitors, and increase in awareness about available treatment options for eosinophilic asthma. In October 2018, Sanofi received the U.S. Food and Drug Administration (FDA) approval for Dupixent (dupilumab), indicated for moderate-to-severe asthma in individuals aged 12 years and older, with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Eosinophilic Asthma Treatment Market: Segmentation
The global eosinophilic asthma treatment market can be segmented based on type of medication, route of administration, and region. In terms of type of medication, the market can be classified into long term control medications, short acting medications, and biologic therapies. Based on route of administration, the global eosinophilic asthma treatment market can be categorized into oral, rectal, intravenous, and nasal. The nasal segment is projected to be driven by increase in the use of nasal sprays for the treatment of asthma. In August 2016, the European Commission granted approval and marketing authorization for Cinqaero, indicated for the treatment of patients with severe eosinophilic asthma.
Eosinophilic Asthma Treatment Market: Regional Analysis
In terms of region, the global eosinophilic asthma treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018 and the trend is anticipated to continue during the forecast period. The U.S. is expected to expand at a high CAGR during the forecast period, attributed to increase in the number of drugs receiving FDA approvals and large number of promising drugs in pipeline. For instance, in November 2017, AstraZeneca received the FDA approval for Fasenra (benralizumab) indicated as an add-on maintenance treatment of patients with severe asthma aged 12 years and above and with an eosinophilic phenotype. The market in Canada is likely to be driven by approvals and launch of new products. In February 2018, Health Canada approved Fasenra (benralizumab injection), manufactured by AstraZeneca, as an add-on maintenance treatment for adult patients with severe eosinophilic asthma. The market in Europe is projected to grow at a rapid pace during the forecast period, driven by acquisition of product portfolios, increase in research activities by pharmaceutical companies, and product approvals & market authorization by regulatory bodies. In November 2016, CHIESI Farmaceutici S.p.A. acquired Atopix Therapeutics Limited, a clinical stage biotechnology company based in the U.K., to expand its product pipeline in respiratory disorders, especially in eosinophilic airways diseases. Asia Pacific is anticipated to be a potential market during the forecast period due to increase in awareness about nasal route of drug administration for eosinophilic asthma, rise in the number of companies seeking regulatory approvals, and surge in the availability of treatment options for asthma patients. In January 2018, the Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca’s Fasenra.
Eosinophilic Asthma Treatment Market: Competitive Landscape
Key players operating in the global eosinophilic asthma treatment market are Sanofi, AstraZeneca, GlaxoSmithKline plc, and Teva Pharmaceutical Industries Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.